Analyst Price Target is $128.00
▲ +36.68% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Cortexyme in the last 3 months. The average price target is $128.00, with a high forecast of $200.00 and a low forecast of $34.00. The average price target represents a 36.68% upside from the last price of $93.65.
Current Consensus is
The current consensus among 5 investment analysts is to hold stock in Cortexyme. This rating has held steady since April 2021, when it changed from a Buy consensus rating.
Cortexyme, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. Its pipeline comprises COR388, COR588, COR788, COR822, and Coronavirus 3CL protease inhibitor. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.